Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.92−0.06 (-6.39%)
Close on Nov 20, 2026Market cap $92.40MP/E –Yield –
Cellectis gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2025 it was $72.95M, up 75.8% from the year before. The highest annual figure on record is $72.95M in fiscal 2025.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.95M | +75.8% |
| FY2024 | Dec 31, 2024 | $41.51M | +230483.3% |
| FY2023 | Dec 31, 2023 | $18.00K | -99.9% |
| FY2022 | Dec 31, 2022 | $17.40M | -39.0% |
| FY2021 | Dec 31, 2021 | $28.50M | -42.0% |
| FY2020 | Dec 31, 2020 | $49.11M | +1192.9% |
| FY2019 | Dec 31, 2019 | $3.80M | -62.0% |
| FY2018 | Dec 31, 2018 | $9.99M | -55.7% |
| FY2017 | Dec 31, 2017 | $22.57M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2023 | Jun 30, 2023 | $123.00K | -63.5% |
| Q2 FY2022 | Jun 30, 2022 | $978.00K | – |
| Q2 FY2021 | Jun 30, 2021 | -$578.00K | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.93M | – |
| Q2 FY2019 | Jun 30, 2019 | $337.00K | – |
See a number that looks wrong?